ZAZZI MAURIZIO | Professor page

Saladini, F., Giammarino, F., Maggiolo, F., Ferrara, M., Cenderello, G., Celesia, B.M., et al. (2023). Residual phenotypic susceptibility to doravirine in multidrug resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 106737 [10.1016/j.ijantimicag.2023.106737]. - view more
Rhee, S., Schapiro, J.M., Saladini, F., Zazzi, M., Khoo, S., Shafer, R.W. (2023). Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance. AIDS RESEARCH AND THERAPY, 20(1), 1-7 [10.1186/s12981-023-00503-5]. - view more
Marchi, S., Dragoni, F., Boccuto, A., Idoko, O.T., Zazzi, M., Sow, S., et al. (2023). Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage. ACTA TROPICA, 237, 106736 [10.1016/j.actatropica.2022.106736]. - view more
Kuznetsova, A., Lebedev, A., Gromov, K., Kazennova, E., Zazzi, M., Incardona, F., et al. (2022). Pre-existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first-line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus-infected patients. CLINICAL CASE REPORTS, 10(2), e05373 [10.1002/ccr3.5373]. - view more
Rossetti, B., Ferrara, M., Taramasso, L., Bai, F., Lombardi, F., Ciccarelli, N., et al. (2022). THE EFFECTS OF SWITCHING FROM DOLUTEGRAVIR/ABACAVIR/LAMIVUDINE TO BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE IN VIROLOGICALLY SUPPRESSED PEOPLE LIVING WITH HIV ON NEUROPSYCHIATRIC SYMPTOMS: PRELIMINARY FINDINGS FROM A RANDOMIZED STUDY. In Atti al 14th Congresso ICAR 2022 (Italian Conference on AIDS and Antiviral Research). - view more

All publications